These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://kianapflb452408.free-blogz.com/86424779/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide